Jim Burns, who had headed Sanofi’s R&D ops in Boston, is jumping ship to take the helm of Casebia Therapeutics, the $335 million gene editing JV created by Bayer and CRISPR Therapeutics $CRSP. Casebia recently inked a big lease in the heart of Kendall Square. “With access to cutting-edge gene-editing CRISPR/Cas9 technology, protein engineering expertise, a strong financial foundation, and with Boston’s incredible network of talent and partners, we have all the tools needed to create a potentially transformative new class of therapies for patients,” Burns said.
Five days after Opexa $OPXA triggered a meltdown in its share price by announcing true failure of its Phase IIb study for an experimental drug for multiple sclerosis, the company has come back with a reorganization that will cost 40% of the jobs at The Woodlands, TX-based biotech. Joining the exodus is Donna Rill, Opexa’s chief development officer, and Scott Seaman, a member of the board as Opexa scouts for a survival plan.
Denmark’s Acesion Pharma has raised a 9.1 million euro round from Novo Seeds and Wellcome Trust. The biotech is developing a small molecule for atrial fibrillation.
The Wall Street Journal reports that cash-strapped Valeant is in advanced talks to sell its stomach drug business Salix to Takeda for $10 billion. The sale would help ease Valeant’s debt while giving a resurgent Takeda new drugs to expand its revenue.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.Free Subscription